{"id":"NCT01620489","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment","officialTitle":"Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-14","primaryCompletion":"2013-08-20","completion":"2013-08-20","firstPosted":"2012-06-15","resultsPosted":"2014-10-30","lastUpdate":"2019-03-19"},"enrollment":279,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Lira 1.8 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.\n\nThe trial medication will be add-on to the subject's stable pre-trial OAD and/or insulin regimen.","primaryOutcome":{"measure":"Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"Lira 1.8 mg","deltaMin":-1.05,"sd":0.8944},{"arm":"Placebo","deltaMin":-0.38,"sd":0.8797}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":97,"countries":["United States","France","Poland","Russia","Ukraine","United Kingdom"]},"refs":{"pmids":["26681713","30663196","39963952","29729957"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":140},"commonTop":["Nausea","Lipase increased","Nasopharyngitis","Vomiting","Glomerular filtration rate decreased"]}}